文献

重组抗小鼠CD137 (TNFRSF9 or 4-1BB)单克隆抗体(克隆号3H3) ，大鼠IgG2a Kappa（Recombinant Anti-mouse CD137 (TNFRSF9 or 4-1BB) Monoclonal Antibody (Clone: 3H3), Rat IgG2a Kappa，货号：PA007486.r2a Syd Labs）

抗小鼠CD137单抗（又称3H3抗体）是一种特异性识别小鼠CD137分子（亦称为TNFRSF9或4-1BB）的高亲和力单克隆抗体。CD137作为肿瘤坏死因子受体超家族成员，主要在活化的T细胞、自然杀伤细胞及其他免疫细胞表面诱导表达，通过与其配体结合传递强效的共刺激信号，在调节T细胞活化、增殖及抗肿瘤免疫应答中具有关键作用。在现代免疫学与肿瘤免疫治疗研究中，抗小鼠CD137(TNFRSF9 or 4-1BB)单抗（3H3抗体）被广泛应用于流式细胞术检测、体外免疫细胞激活，以及在体内荷瘤模型中评估4-1BB共刺激效应对免疫调节的深远影响。

作为专业的生命科学试剂供应商，Syd Labs推出的重组抗小鼠CD137(TNFRSF9 or 4-1BB)单抗（克隆号3H3）采用高效的哺乳动物细胞表达系统进行重组生产，确保了批次间极高的稳定性与批次一致性。该产品完全达到严格的体内实验级标准，具备超低的内毒素水平，且采用Human IgG1 Fc Silent Kappa格式进行工程化突变改造，能够有效消除Fc段与巨噬细胞或树突状细胞表面Fc受体的非特异性结合干扰。无论是用于流式细胞术表型分析还是开展高要求的体内免疫干预实验，Syd Labs重组3H3抗体都能为您提供高特异性与可靠的实验数据支持。

抗小鼠CD137(TNFRSF9 or 4-1BB)单抗(3H3)流式部分参考文献:

1. Preclinical characterization and phase 1 results of ADG106, a non-fucosylated agonistic anti-CD137 antibody for the treatment of advanced solid tumors and non-Hodgkin’s lymphoma
Wang Z, et al. Cell Rep Med. 2024 Feb 20;5(2):101397. PMID: 38330942
“To assess ADG106 in a murine tumor model, syngeneic mice bearing MC38 tumors were treated with ADG106 or 3H3 antibody. Flow cytometry analysis showed increased CD8+ T cell infiltration in tumors treated with ADG106 compared to 3H3. The antibody 3H3 was used as a positive control for CD137 agonism. Peripheral blood samples were stained for CD137 expression using 3H3. Data were acquired on a BD FACSCelesta flow cytometer.”

2. TCR-independent CD137 (4-1BB) signaling promotes CD8+ T cell expansion and effector function
Liu S, et al. Immunity. 2023 Jul 11;56(7):1465-1482.e6. PMID: 37392737
“Cells were stained with anti-CD137 antibody (clone 3H3, BioLegend) for flow cytometry to assess expression levels. The 3H3 antibody was used to gate CD137+ CD8+ T cells in tumor-infiltrating lymphocytes. Flow cytometry was performed on a BD LSRFortessa. CD8+ T cell expansion was measured by CFSE dilution in the presence of 3H3 stimulation. Data analysis was conducted using FlowJo v10.”

3. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Gavilán A, et al. J Immunother Cancer. 2022 Mar;10(3):e003532. PMID: 35236742
“CD137 agonist therapy was provided by 5 μg of anti- CD137 (clone 3H3, BioXcell) intratumorally administered three times with a 3- day interval. Similarly, isolated mouse CD8 T cells from splenocytes were activated for 72 hours in plates coated with the mAbs anti- CD3 ε (17A2, 0.5 μg/mL), anti- CD137 (3H3, 10 μg/ mL), anti- CD28 (37.51, 5 μg/mL) and/or RatIgG2a isotype control (RTK2758)…”

4. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
Madireddi S, et al. JCI Insight. 2020 Mar 12;5(5):e133647. PMID: 32161196
“In order to understand the effect of epitope and in vitro potency on in vivo activity, we compared CTX-471-AF with the urelumab-like mouse surrogate antibody 3H3. To assess the potential of CTX-471, CTX-471-AF, and 3H3 to induce liver inflammation, we administered up to 80 mg/kg of these antibodies to nontumor-bearing mice by weekly i.v. injections…”

5. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on CD8+ T Cells
Gasparian S, et al. Cancer Immunol Res. 2021 Mar;9(3):325-338. PMID: 32273279
“A different anti-mouse CD137 (clone 3H3) was also tested in this assay and showed crosslink-independent activity, similar to that seen with Fab clone 20H4.9 (Fig. 3A and Supplemental Fig. S6A and S6B). The results showed a clear difference between the two CD137 agonist antibodies tested, clone 3H3 induced a sustained increase in T cell infiltration, proliferation and activation in the liver and spleen…”